2023年5月3日

欧陆坊GeLaMed提供检测组件处理ColoAlert®通过德国。伯克利分校美国-美因茨,德国美因茨(2023年5月3日)——生物医学公司(纳斯达克:MYNZ)(“美因茨生物医学”或“公司”),分子遗传学诊断公司专攻癌症的早期检测,今天宣布将欧陆坊GeLaMed加入其网络实验室的合作伙伴所提供的PCR检测组件处理ColoAlert®,其旗舰产品,是一种高度有效的和易于使用的家庭结直肠癌(CRC)的筛检试验。欧陆坊GeLaMed有四个位置在德国和是欧陆坊科学的一部分,一个国际实验室集团在61个国家拥有超过61000名员工,每年进行4.5亿多个测试。欧陆坊GeLaMed为其客户提供了一个广泛的高质量的服务在十一医疗部门涵盖高级和现代诊断选项在人类遗传学、医学微生物学、医学和分子诊断实验室。根据GeLaMed,近500员工每个工作日处理超过15000的订单,提供超过2000种不同的分析方法从实验室医学和微生物组合医学专家的指导下。业务线主管马库斯Cholewa临床诊断达奇在欧陆坊,表达了对美因茨之间的协作的兴奋生物医学和欧陆坊GeLaMed,说明欧陆坊总是致力于提供优秀的客户服务,质量,和先进的解析解,以及最全面的测试方法。他还提到欧陆坊有引进创新和高价值的历史诊断测试产品,通过合作,他们可以协助确定结直肠癌(CRC),为患者提供个性化信息来有效地管理自己的健康。根据协议条款,欧陆坊GeLaMed将提供ColoAlert®美因茨在其测试网站和生物医学与医生和患者教育项目将协助产品发布的一部分,强调早期筛查的重要性CRC的检测和预防。关于ColoAlert®ColoAlert®,美因茨生物医学的旗舰产品,提供了在用户友好的高敏感性和特异性,家庭结直肠癌(CRC)筛查工具。这种非侵入性的测试可以表明肿瘤由肿瘤DNA分析,提供更好的早期检测粪便隐血试验(FOBT)。 Based on PCR-technology, ColoAlert® detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis ( Gies et al., 2018 ). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert® will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country. About Colorectal Cancer Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert® should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US. About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn , Twitter and Facebook . For media inquiries, please contact press@mainzbiomed.com In Europe: